HUP0103622A2 - Nem peptid típusú GnRH hatóanyagok és az előállításukra szolgáló módszerek és intermedierek és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Nem peptid típusú GnRH hatóanyagok és az előállításukra szolgáló módszerek és intermedierek és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0103622A2
HUP0103622A2 HU0103622A HUP0103622A HUP0103622A2 HU P0103622 A2 HUP0103622 A2 HU P0103622A2 HU 0103622 A HU0103622 A HU 0103622A HU P0103622 A HUP0103622 A HU P0103622A HU P0103622 A2 HUP0103622 A2 HU P0103622A2
Authority
HU
Hungary
Prior art keywords
group
substituted
atoms
unsubstituted alkyl
alkynyl
Prior art date
Application number
HU0103622A
Other languages
English (en)
Inventor
Mark Brian Anderson
Lance Christopher Christie
James Faust
Yufeng Hong
Haitao Li
David Robert Luthin
Genevieve Deguzman Paderes
Ved P. Pathak
Eileen Valenzuela Tompkins
Haresh N. Vazir
Original Assignee
Agouron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals, Inc. filed Critical Agouron Pharmaceuticals, Inc.
Publication of HUP0103622A2 publication Critical patent/HUP0103622A2/hu
Publication of HUP0103622A3 publication Critical patent/HUP0103622A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A tal lm ny a gonadotropin-leadó hormon hat s t g tló nem peptidtípusú GnRH hatóanyagokra vonatkozik. Az (I) ltal nos képletűvegyületek, gyógy szatilag elfogadható sóik, multimerjeik,elővegyületeik és aktív metabolitjaik emlős"k reprodukciósrendellenességei, szteroid hormonfüggő tumorok kezelésére és atermékenység szab lyoz s ra haszn lhatók. A tal lm ny a vegyületek elő llít s ra szolg ló elj r sokat és azelj r sokban haszn lt intermediereket is mag ban foglalja és kiterjeda vegyületeket tartalmazó gyógyszerkészítményekre is. Az (I) ltal nosképletben X jelentése C=O, C=S, S=O és S(O)2; (het) jelentése 5 tagúheterociklusos gyűrű, amely 1-4, előny"sen 2-3 heteroatomot tartalmaz,amely nitrogénatom, oxigénatom vagy kénatom lehet, és ahol a gyűrűlehet telített, részben telítetlen, teljesen telítetlen vagy arom s;R1 és R2 jelentése egym stól függetlenül hidrogénatom vagy kisszénatomsz mú alkilcsoport; R3 jelentése hidrogénatom, halogénatom,szubsztitu lt vagy szubsztitu latlan alkil-, alkenil-, alkinil-,cikloalkilcsoport, heterociklusos csoport, aril-, heteroarilcsoport, -CH2OR, -OR vagy -C(O)OR ltal nos képletű csoport, ahol R jelentéseszubsztitu lt vagy szubsztitu latlan alkil-, alkenil-, alkinil-,cikloalkilcsoport, heterociklusos csoport, aril- vagyheteroarilcsoport, ahol a szénatomok sz m nak "sszege, az adottesetben jelenlevő szubsztituenseket nem sz mítva, 1-12; R4 és R5jelentése egym stól függetlenül hidrogénatom, halogénatom, szubsztitult vagy szubsztitu latlan alkil-, alkenil-, alkinil-,cikloalkilcsoport, heterociklusos csoport, aril-, heteroarilcsoport, -CH2OR, -OR vagy -C(O)OR ltal nos képletű csoport, ahol R jelentése afentiekben meghat rozott, R6 és R7 jelentése egym stól függetlenülhidrogénatom, halogénatom, szubsztitu lt vagy szubsztitu latlanalkil-, alkenil-, alkinil-, cikloalkilcsoport, heterociklusos csoport,aril-, heteroarilcsoport, -CH2OR, -OR vagy -C(O)OR ltal nos képletűcsoport, ahol R jelentése a fentiekben meghat rozott, és ahol aszénatomok sz m nak "sszege, az adott esetben jelen levőszubsztituenseket nem sz mítva, 1-12; vagy R6 és R7 a kapcsolódóatomokkal együtt egy adott esetben szubsztitu lt 5-6 tagú gyűrűtalkot, amelyek 5-7 heteroatomot tartalmazhatnak, amelyek nitrogén-,oxigén- vagy kénatomok lehetnek; R8 jelentése lipofil csoport, amelyeta k"vetkezőkben felsoroltak k"zül v laszthatunk: szubsztitu lt vagyszubsztitu latlan alkil-, alkenil-, alkinil-, cikloalkilcsoport,heterociklusos csoport, aril-, heteroarilcsoport, -CH2OR, -OR vagy -C(O)OR ltal nos képletű csoport, ahol R jelentése a fentiekben meghatrozott, és ahol a szénatomok sz m nak "sszege, az adott esetben jelenlevő szubsztituenseket nem sz mítva, 6-20; R9 jelentése hidrogénatomvagy szubsztitu lt vagy szubsztitu latlan alkilcsoport, előny"senkisszénatomsz mú
HU0103622A 1998-08-20 1999-08-20 Non-peptide gnrh agents, methods and intermediates for their preparation and medicaments containing them HUP0103622A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9752098P 1998-08-20 1998-08-20
PCT/US1999/018790 WO2000020358A2 (en) 1998-08-20 1999-08-20 NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION

Publications (2)

Publication Number Publication Date
HUP0103622A2 true HUP0103622A2 (hu) 2002-04-29
HUP0103622A3 HUP0103622A3 (en) 2003-01-28

Family

ID=22263796

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103622A HUP0103622A3 (en) 1998-08-20 1999-08-20 Non-peptide gnrh agents, methods and intermediates for their preparation and medicaments containing them

Country Status (33)

Country Link
EP (1) EP1105120B1 (hu)
JP (1) JP2002535244A (hu)
KR (1) KR20010085402A (hu)
CN (1) CN1379666A (hu)
AP (1) AP2001002053A0 (hu)
AT (1) ATE291423T1 (hu)
AU (1) AU759310B2 (hu)
BG (1) BG105362A (hu)
BR (1) BR9913374A (hu)
CA (1) CA2341346A1 (hu)
CZ (1) CZ2001523A3 (hu)
DE (1) DE69924387D1 (hu)
EA (1) EA200100255A1 (hu)
EE (1) EE200100102A (hu)
ES (1) ES2237966T3 (hu)
GE (1) GEP20043315B (hu)
HR (1) HRP20010206A2 (hu)
HU (1) HUP0103622A3 (hu)
ID (1) ID29244A (hu)
IL (1) IL141396A0 (hu)
IS (1) IS5846A (hu)
LT (1) LT4904B (hu)
LV (1) LV12732B (hu)
NO (1) NO20010309L (hu)
NZ (1) NZ509252A (hu)
OA (1) OA11599A (hu)
PL (1) PL356984A1 (hu)
SI (1) SI20746A (hu)
SK (1) SK2262001A3 (hu)
TR (1) TR200100631T2 (hu)
WO (1) WO2000020358A2 (hu)
YU (1) YU13701A (hu)
ZA (1) ZA200100831B (hu)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0983992B1 (en) * 1992-04-22 2005-10-26 Ligand Pharmaceuticals Incorporated Compounds having selectivity for retinoid x receptors
CA2368047A1 (en) * 1999-03-24 2000-09-28 Anormed Inc. Chemokine receptor binding heterocyclic compounds
AR024158A1 (es) * 1999-06-01 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
AU2002312348A1 (en) * 2001-06-06 2002-12-16 Agouron Pharmaceuticals, Inc. Non-peptide gnrh agents, pharmaceutical compositions and methods for their uses, and processes for preparing them
PT1401825E (pt) 2001-06-11 2009-10-23 Virochem Pharma Inc Compostos e métodos para o tratamento ou para a prevenção de infecções com flavivírus
US7132438B2 (en) 2001-10-09 2006-11-07 Amgen Inc. Benzimidazole derivatives
GB0126292D0 (en) * 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
JP2005170790A (ja) * 2002-01-09 2005-06-30 Ajinomoto Co Inc N−アルキルスルフォニル置換アミド誘導体
US6521395B1 (en) * 2002-01-30 2003-02-18 Eastman Kodak Company Infrared couplers for incorporating and recovering metadata
WO2003068769A1 (en) * 2002-02-12 2003-08-21 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
MXPA04012566A (es) * 2002-06-13 2005-04-19 Pfizer Agentes no peptidicos reguladores de la gnrh, composiciones farmaceuticas y procedimientos para su uso.
JP2006510725A (ja) * 2002-11-20 2006-03-30 パラダイム・セラピューティクス・リミテッド 複素環式ケイ素化合物、ならびにGnRH(ゴナドトロピン放出ホルモン)と関係のある疾患または状態の治療におけるその使用
CN101475528A (zh) * 2003-03-31 2009-07-08 大正制药株式会社 新的喹啉、四氢喹唑啉和嘧啶衍生物以及与其应用有关的治疗方法
EP1464335A3 (en) * 2003-03-31 2007-05-09 Taisho Pharmaceutical Co. Ltd. Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist
US7427683B2 (en) * 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
CA2536964A1 (en) * 2003-04-25 2004-11-11 Ortho-Mcneil Pharmaceutical, Inc. C-fms kinase inhibitors
EP1628661A2 (en) * 2003-06-05 2006-03-01 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
DK1648906T3 (da) * 2003-07-09 2008-02-04 Takeda Cambridge Ltd Organo-silicium-forbindelser og deres anvendelse
US7407649B2 (en) 2003-07-10 2008-08-05 Paradigm Therapeutics Ltd Silicon compounds and their use
WO2005039564A1 (en) * 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
US20090291915A1 (en) * 2004-12-17 2009-11-26 Graham Andrew Showell Silicon Compounds and Their Use
CN101218224B (zh) 2005-05-13 2013-05-08 Viro化学制药公司 治疗或预防黄病毒感染的组合物和方法
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
NZ564222A (en) 2005-06-14 2011-10-28 Taigen Biotechnology Co Ltd Pyrimidine compounds
CA2613162A1 (en) * 2005-06-28 2007-01-04 Takeda Cambridge Limited Heterocyclic non-peptide gnrh antagonists
DK1910384T3 (da) * 2005-08-04 2012-12-17 Sirtris Pharmaceuticals Inc Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser
CN101437519A (zh) 2006-03-31 2009-05-20 艾博特公司 吲唑化合物
WO2007131996A1 (en) * 2006-05-12 2007-11-22 Genmedica Therapeutics Sl Meta-xylylenediamine vanadate salts
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
NZ584475A (en) * 2007-10-11 2012-07-27 Vertex Pharma Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
CN101888991A (zh) 2007-10-31 2010-11-17 财团法人乙卯研究所 类视色素前体药物化合物
EA019289B1 (ru) 2008-04-21 2014-02-28 Тайджен Байотекнолоджи Ко., Лтд. Производные аминопиридина, аминопиримидина и амино-1,3,5-триазина
UY31984A (es) * 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas.
TW201021855A (en) 2008-11-13 2010-06-16 Taigen Biotechnology Co Ltd Lyophilization formulation
WO2012018668A1 (en) 2010-08-05 2012-02-09 Amgen Inc. Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase
CN102050823A (zh) * 2010-10-27 2011-05-11 华东理工大学 新型光稳定剂-鸟嘌呤类似物的合成及表征
WO2012112567A1 (en) * 2011-02-15 2012-08-23 Georgetown University Small molecule inhibitors of agbl2
CA2836311A1 (en) 2011-05-16 2012-11-22 Bionomics Limited Amine derivatives as potassium channel blockers
CN103827097B (zh) * 2011-07-26 2016-03-16 赛诺菲 3-杂芳酰基氨基-丙酸衍生物及其作为药物的用途
WO2013067578A1 (en) * 2011-11-07 2013-05-16 The University Of Queensland Modulators of c3a receptors
AU2013333657B2 (en) * 2012-10-17 2018-04-26 Exonate Limited Compounds useful for treating ocular neovasculan
GB201300304D0 (en) * 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
WO2017070235A1 (en) * 2015-10-19 2017-04-27 Attenua, Inc. Antitussive compositions and methods
EP3679027A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydrobenzimidazolones
EP3935050A4 (en) 2019-03-06 2023-01-04 C4 Therapeutics, Inc. HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3499002A (en) * 1968-06-20 1970-03-03 Robins Co Inc A H 1-carbamoyl-3-aroylpyrrolidines
NL6913261A (hu) * 1968-09-09 1970-03-11
US3932444A (en) * 1972-04-28 1976-01-13 E. I. Du Pont De Nemours & Co. 4-Imidazolylsulfonylimidazoles
US4013647A (en) * 1976-03-23 1977-03-22 American Home Products Corporation Morpholine containing tetrazole-5-carboxamide derivatives
GB1491776A (en) * 1976-09-08 1977-11-16 Pfizer Ltd Thiadiazoles
US4096153A (en) * 1977-01-21 1978-06-20 American Home Products Corporation Arylene-bis-tetrazole-5-carboxamides
US5236928A (en) * 1991-03-19 1993-08-17 Merck & Co., Inc. Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists
JPH06509075A (ja) 1991-07-01 1994-10-13 ユニヴァーシティ テクノロジーズ インターナショナル インコーポレイテッド GnRH及び他の生物学的に活性なリガンドの非感度低下性類縁体
WO1993013083A1 (en) * 1991-12-31 1993-07-08 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
ATE243204T1 (de) * 1995-08-24 2003-07-15 Basf Ag Isoxazole- und isothiazole-5-carboxamid derivate, deren herstellung und deren verwendung als herbizide
JP3092946B2 (ja) * 1995-12-14 2000-09-25 メルク エンド カンパニー インコーポレーテッド ゴナドトロピン放出ホルモン拮抗剤
CA2254769A1 (en) * 1996-05-20 1997-11-27 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5878393A (en) * 1996-09-09 1999-03-02 Matsushita Electric Industrial Co., Ltd. High quality concatenative reading system

Also Published As

Publication number Publication date
WO2000020358B1 (en) 2001-01-04
DE69924387D1 (de) 2005-04-28
WO2000020358A3 (en) 2000-11-16
LV12732A (en) 2001-10-20
EP1105120B1 (en) 2005-03-23
ATE291423T1 (de) 2005-04-15
NZ509252A (en) 2004-05-28
LV12732B (en) 2002-03-20
ES2237966T3 (es) 2005-08-01
IL141396A0 (en) 2002-03-10
EA200100255A1 (ru) 2002-02-28
NO20010309D0 (no) 2001-01-19
YU13701A (sh) 2005-06-10
ID29244A (id) 2001-08-16
LT4904B (lt) 2002-04-25
SK2262001A3 (en) 2002-12-03
HRP20010206A2 (en) 2004-02-29
JP2002535244A (ja) 2002-10-22
GEP20043315B (en) 2004-02-10
BR9913374A (pt) 2001-05-15
AU759310B2 (en) 2003-04-10
CN1379666A (zh) 2002-11-13
EE200100102A (et) 2002-06-17
CA2341346A1 (en) 2000-04-13
NO20010309L (no) 2001-04-11
BG105362A (en) 2001-12-31
KR20010085402A (ko) 2001-09-07
TR200100631T2 (tr) 2002-08-21
CZ2001523A3 (cs) 2002-05-15
AP2001002053A0 (en) 2001-03-31
SI20746A (sl) 2002-06-30
LT2001024A (en) 2001-11-26
ZA200100831B (en) 2002-08-22
IS5846A (is) 2001-02-16
WO2000020358A2 (en) 2000-04-13
HUP0103622A3 (en) 2003-01-28
PL356984A1 (en) 2004-07-12
EP1105120A4 (en) 2001-12-19
OA11599A (en) 2004-08-23
AU2470900A (en) 2000-04-26
EP1105120A2 (en) 2001-06-13

Similar Documents

Publication Publication Date Title
HUP0103622A2 (hu) Nem peptid típusú GnRH hatóanyagok és az előállításukra szolgáló módszerek és intermedierek és ezeket tartalmazó gyógyszerkészítmények
HUP0105113A2 (hu) Benzoheterociklusos vegyületek és MEK inhibitorokként történő alkalmazásuk és a vegyületeket tartalmazó gyógyászati készítmények
HUP0102543A2 (hu) Szexuális rendellenességek kezelésére alkalmas, cGMP PDE inhibitor hatású pirazolopiramidinon-származékok és ezeket tartalmazó gyógyszerkészítmények
HUP0203971A2 (hu) Imidazoimidazolok és -triazolok mint gyulladásellenes szerek és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0203316A2 (hu) Amino-triazolopiridin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0301422A2 (hu) Ösztrogén hatású szereket tartalmazó gyógyászati készítmények
HUP0203895A2 (hu) Szubsztituált azaindolok és ilyen vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
MY102866A (en) Amide derivatives.
HUP0004400A2 (hu) Dipeptid-nitrilek, eljárás előállításukra, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0100280A2 (hu) Pirrolo-, tieno-, furano- és pirazolo [3,4d] piridazonok, eljárás az előállításukra és ezeket tartalmazó gyógyászati készítmények
HUP0302475A2 (hu) Eljárás allergia kezelésére szubsztituált pirazolok alkalmazásával
NO306778B1 (no) Heterocyklisk aromatisk oksazolforbindelse, mellomprodukter, farmasöytiske preparater inneholdende forbindelsene, rene cyklooksagenase-2 inhibitorer samt et antiinflammatorisk middel
HUP0202017A2 (hu) Új vegyületek
KR890008155A (ko) 신규인 유도체, 그 제조방법 및 의약에서의 사용
ES8107201A1 (es) Un procedimiento para la preparacion de derivados de morfo- lina
HUP0204458A2 (hu) Alfa-2-antagonista hatású kinolinszármazékok és ezeket tartalmazó gyógyszerkészítmények
HUP9901096A2 (hu) Indolszármazékok, előállításuk és alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények
NO800447L (no) Derivater av difenylhydantoin, farmasoeytiske preparater inneholdende slike preparater, samt fremgangsmaate til fremstilling av de aktive forbindelser
HUP0103072A2 (hu) Növekedési hormon kiválasztást elősegítő vegyületek alkalmazása
HUP0102500A2 (hu) Növekedési hormon szekretagógok alkalmazása szisztémás lupus erythematosus és gyulladásos bélbetegség kezelésére és ezeket tartalmazó gyógyszerkészítmények
HUP0100184A2 (hu) Szubsztituált 2-(benzil-amino)-2-fenil-acetamid-vegyületek és ezeket tartalmazó gyógyszerkészítmények
ES8207124A1 (es) Un procedimiento para la preparacion de derivados de aminas secundarias.
HUP0203787A2 (hu) Hidroxi-acetil-piperazinnal szubsztituált oxazolidinon-benzoesav-észterek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0301686A2 (hu) Ciklikus kvaterner ammóniumvegyületek alkalmazása köhögés elleni gyógyszerkészítmények előállítására
HUP0300295A2 (hu) Helyettesített benzamidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk